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Abstract: Warfarin therapy reduces morbidity and mortality related to thromboembolism. Yet 
adherence to long-term warfarin therapy remains challenging due to the risks of anticoagulant-
associated complications and the burden of monitoring. The aim of this paper is to review 
determinants of adherence and persistence on long-term anticoagulant therapy for atrial fibril-
lation and venous thromboembolism. We evaluate what the current literature reveals about the 
impact of warfarin on quality of life, examine warfarin trial data for patterns of adherence, and 
summarize known risk factors for warfarin discontinuation. Studies suggest only modest adverse 
effects of warfarin on quality of life, but highlight the variability of individual lifestyle experi-
ences of patients on warfarin. Interestingly, clinical trials comparing anticoagulant adherence 
to alternatives (such as aspirin) show that discontinuation rates on warfarin are not consistently 
higher than in control arms. Observational studies link a number of risk factors to warfarin 
non-adherence including younger age, male sex, lower stroke risk, poor cognitive function, 
poverty, and higher educational attainment. In addition to differentiating the relative impact of 
warfarin-associated complications (such as bleeding) versus the lifestyle burdens of warfarin 
monitoring on adherence, future investigation should focus on optimizing patient education and 
enhancing models of physician–patient shared-decision making around anticoagulation.
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Introduction
Therapy with vitamin K antagonists such as warfarin is highly effective in reduc-
ing morbidity and mortality related to thromboembolism. Numerous trials have 
demonstrated a clear benefit to treating patients with atrial fibrillation and consensus 
guidelines now recommend routine anticoagulation in many patient groups with atrial 
fibrillation.1,2 Similarly, some guidelines have advocated for indefinite anticoagula-
tion in certain subsets of patients with venous thromboembolism.3 At the same time, 
recent efforts to enhance patient safety have identified anticoagulants as “high risk” 
medications,4 the proper use of which requires particular scrutiny to maximize clinical 
safety.5 Despite data supporting the use of long-term anticoagulation in a number of 
patients and increases in physician prescription of appropriate anticoagulant therapy,6,7 
maintaining patient adherence on long-term warfarin therapy remains a significant 
challenge due to the risks of anticoagulant-associated bleeding complications and the 
burdens of frequent monitoring and dose-adjustment. Moreover, provider concerns 
around patient compliance with anticoagulant regimens likely prevent more widespread 
adoption of indicated anticoagulation therapy.8Patient Preference and Adherence 2010:4 52
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The aim of this paper is to review known determinants of 
patient adherence and persistence on long-term anticoagulant 
therapy for atrial fibrillation and venous thromboembolism. 
We evaluate what the current literature reveals about the 
impact of warfarin use on quality of life, evaluate existing 
clinical data to identify patterns of patient adherence to 
warfarin, and summarize what is known about the major risk 
factors that influence warfarin discontinuation.
Common indications for long-term 
anticoagulation with warfarin
Prolonged warfarin therapy is indicated in a number of clini-
cal scenarios other than atrial fibrillation and venous throm-
boembolism, including for prosthetic heart valves.2 However, 
clinical application of available guidelines for atrial fibrilla-
tion and venous thromboembolism remains somewhat unique 
in that patient preference and values are emphasized as 
important contributors to the decision to begin and maintain 
warfarin therapy.1,3 Also, physicians demonstrate reluctance 
to strictly follow guidelines in atrial fibrillation and venous 
thromboembolism in part due to the perceived barriers to 
warfarin success in their patients as well as recognition that 
guidelines around appropriate anticoagulation are difficult 
to generalize to all patients.8–10 In other words, indefinite 
warfarin use in atrial fibrillation and venous thromboembo-
lism can be viewed by some patients and clinicians as more 
optional and subject to ongoing comparisons of the risks and 
benefits of therapy. As such, these clinical scenarios offer 
a unique opportunity to evaluate the way patient behaviors 
and preferences impact medication adherence.
Atrial fibrillation
Atrial fibrillation is the most common clinically significant 
arrhythmia, affecting around 2.5 million people in the United 
States – a number bound to rise dramatically as the population 
ages in coming decades.11,12 Atrial fibrillation is an important 
independent risk factor for stroke, accounting for 15% of all 
strokes in the US and up to 36% of all strokes occurring in 
patients 80 to 89 years old.13 Overall, atrial fibrillation confers 
a 4- 5-fold increase in ischemic stroke risk, and patients left 
untreated for atrial fibrillation face a 4.5% risk per year of 
suffering a stroke.14,15
Numerous well-designed clinical trials demonstrate that 
oral vitamin K antagonists such as warfarin sodium sub-
stantially reduce the risk of atrial fibrillation-related stroke, 
such that treating only 32 patients with atrial fibrillation 
prevents 1 stroke.16–21 Moreover, adjusted-dose warfarin is 
superior to available alternative treatment options, such as 
anti-platelet therapy with clopidogrel and aspirin.1 Based 
on the cumulative clinical trial data weighing the benefit 
of stroke prevention versus the risk of adverse effects from 
warfarin such as bleeding, consensus opinion recommends 
long-term (lifelong) warfarin treatment (goal INR 2.0–3.0) 
in patients with additional risk factors for stroke, such as 
previous stroke, older age, hypertension, diabetes mellitus, 
and congestive heart failure.1
venous thromboembolism
Clinically significant venous thromboembolism, particularly 
deep vein thrombosis (DVT) and pulmonary embolism 
(PE), represents a considerable public health concern with 
an annual incidence of about 100 per 100,000 in the general 
population22–24 and with PE causing up to 200,000 deaths 
annually in the US.25 Randomized trials have clearly demon-
strated that at least 3 months of warfarin is more effective in 
preventing recurrent venous thromboembolism than shorter 
durations. However, certain patient sub-groups, such as those 
with active cancer or idiopathic venous thromboembolism, 
have higher rates of recurrent venous thromboembolism and 
thus may benefit from life-long anticoagulation.26,27 At the 
same time, the benefits of reducing venous thromboembolism 
recurrence risk must be balanced with an increased bleeding 
risk and may be strongly influenced by patient preference.3 
Although several promising strategies have been developed 
to help estimate a person’s risk for venous thromboembolism 
recurrence, there remains no validated risk scheme that can 
help clinicians risk-stratify patients to appropriate duration 
of anticoagulation therapy.10,28,29
The 8th American College of Chest Physicians Consensus 
Guidelines currently recommend indefinite anticoagulation 
in the following patient subgroups: (1) patients with a first 
unprovoked proximal DVT without risk factors for bleeding 
and for whom adequate anticoagulant monitoring is achiev-
able, (2) patients with a second unprovoked DVT, (3) patients 
with concomitant cancer.3
Translating evidence-based 
recommendations into  
the clinical setting
Despite evidence supporting long-term anticoagulant therapy 
in certain patients, multiple factors, including the necessity 
of frequent international normalized ratio (INR) monitoring 
and drug-drug and diet interactions make the translation 
of evidence-based recommendations into “real-life” chal-
lenging.1,9 Clearly, tight warfarin control within a narrow 
therapeutic range is an important practical consideration Patient Preference and Adherence 2010:4 53
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since supratherapeutic INRs (especially 4.0) raise the risk 
of severe bleeding complications such as intracranial hemor-
rhage.18,30–32 Likewise, warfarin under-dosing puts patients at 
significant risk for thromboembolism and stroke.33,34 Despite 
the importance of maintaining warfarin in a therapeutic range, 
nearly one-half of patients with atrial fibrillation who had 
stroke despite intention-to-treat with warfarin had inadequate 
anticoagulation (INR  1.5) and 30% were not actively 
taking warfarin at the time of their stroke.15 Data suggest 
that patients maintain a target INR level only about 50% of 
the time35 and that as many as 22%–33% of patients newly 
started on warfarin for atrial fibrillation discontinue therapy 
within the first year of treatment.36–39
Clearly, the appropriate translation of evidence-based 
recommendations to the real world remains a challenge. 
Because many patients benefit from appropriate lifelong 
anticoagulation with warfarin, insights into adherence and 
reasons for discontinuation have critical implications for 
improving the quality of anticoagulant care.
Impact of long-term warfarin 
therapy on quality of life
Warfarin has a narrow therapeutic window, requiring fre-
quent blood tests and dose-adjustments.40 Warfarin effects 
also may vary in response to changes in diet and other 
medications. The challenges in maintaining warfarin in an 
appropriate therapeutic-range combined with increased risk 
of both major and minor bleeding may contribute to dif-
ficulties in convincing patients to take chronic warfarin as 
well as remain compliant with recommended treatment and 
monitoring. Despite methodologic challenges when attempt-
ing to formally quantify quality of life,41 studies have gener-
ally challenged assumptions that long-term warfarin therapy 
significantly and negatively impacts patient quality of life. 
Warfarin appears to have at most a modest impact on quality 
of life, and studies suggest a wide range of interpatient vari-
ability of quality of life experiences on warfarin, supporting 
the merit of incorporating individual patient preferences into 
warfarin treatment decisions.
Health-related quality of life can be estimated as a sub-
jective measure of how physical impediments as well as 
psychological and emotional discomfort impact a person’s 
day-to-day life. A medication’s net impact on a patient’s 
quality of life can be thought of as a balance between the 
potential side effects of a medication, the burden of com-
plying with an appropriate dose of the medication, and the 
medication’s ability to prevent the targeted adverse health 
outcome.42
Qualitative studies and patient interviews have identi-
fied several domains that come into play when considering 
the impact of long-term warfarin therapy on quality of life 
(Table 1). These include the inconvenience of taking the 
medication, inconvenience of frequent blood monitoring, 
perceived efficacy of the medication, perceived safety of 
the medication, anxiety related to potential and actual side 
effects of the medication, patient autonomy, the quality 
of information given to patients by physicians and shared 
decision making before starting the medication, symptom 
alleviation (or prevention), and impact of the medication on 
physical activities.43 In qualitative studies, the most com-
monly cited difficulties for patients on long-term warfarin 
include the burden of regular clinic visits, dietary and alcohol 
restrictions, and worrying about side effects and drug-drug 
interactions.44
However, attempts to formally quantify the effects of 
warfarin on quality of life have found relatively small effects 
even when compared to medications (such as aspirin) that 
do not require the monitoring and restrictions of warfarin. 
This may be related in part to the value patients place on 
the potential of warfarin to prevent adverse health outcomes 
(especially debilitating stroke) over the risk of adverse drug 
effects or inconvenience of the drug regimen.45 Physicians, 
in fact, may tend to over-emphasize the impact of long-term 
warfarin on quality of life, and many have speculated that 
mismatched expectations between physician and patient 
perceptions of risks, benefits, and lifestyle burden of long-
term warfarin may have important implications in under-
prescribing and medication compliance patterns.8,42,44,46
Patients demonstrate considerable variability in their 
quality of life preferences regarding warfarin therapy for 
stroke prevention. One study interviewed patients with 
atrial fibrillation to quantify the impact of stroke using a 
time-tradeoff method and found that 83% considered a 
Table 1 Factors that may influence quality of life for patients 
taking warfarin
inconvenience of taking the medication
Inconvenience of frequent blood monitoring and clinic visits
Perceived efficacy of the medication in preventing adverse outcomes  
(ie, stroke)
Anxiety related to potential and actual side effects of the medication
Anxiety about potential drug-drug interactions
extent of shared decision making between the physician and patient 
when starting the medication
Quality of information given to patients by physicians
impact of the medication on physical activities
Dietary and alcohol restrictionsPatient Preference and Adherence 2010:4 54
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major stroke to be equal or worse than death.41 However, 
about 10% of patients estimated that the same type of stroke 
would decrease their quality of life by less than 50%. These 
patients also generally considered stroke prophylaxis with 
warfarin to have nearly no negative impact on their quality 
of life overall, and about the same as using aspirin for stroke 
prevention. However, 16% of patients estimated their quality 
of life on warfarin so low that treatment with aspirin alone 
would actually be preferred in terms of quality-adjusted life 
expectancy. Acknowledging that indirect measurements of 
quality of life, such as by using time-tradeoff estimation, are 
artificial and difficult to apply to actual patient experience, 
this study indicates that individual patient preference is likely 
to play a role in ultimate adherence to a given prophylaxis 
regimen.
Only one major randomized controlled trial has examined 
in detail the impact of long-term warfarin therapy on quality 
of life.47 This trial randomized patients with non-rheumatic 
atrial fibrillation to adjusted-dose warfarin versus control. 
The study followed patients for over two years and regularly 
assessed quality of life with validated scales measuring 
overall functioning, well-being, and health perceptions. 
Of patients taking warfarin in the study, only 11% of patients 
agreed that “taking warfarin restricts my life-style,” 22% said 
“I worry a lot about the side effects of warfarin,” and 3% 
agreed “I would be more physically active if I did not take 
warfarin.” Overall, no significant differences in global qual-
ity-of-life were found between warfarin and non-warfarin 
treated patients. However, the study noted that bleeding 
complications resulted in worsened adverse health percep-
tions and distress.
Studies of elderly patients (75 years) in the United 
Kingdom used a validated version of the short form (SF)-36 
to measure quality of life before and 6 months after starting 
warfarin therapy for atrial fibrillation and failed to dem-
onstrate a negative quality of life impact from warfarin, 
regardless of length of warfarin therapy.42,48 In another 
study, structured interviews of 21 older patients (average 
age 74 years) with atrial fibrillation on warfarin explored 
patients’ experiences within four domains including “impact 
on daily life” and “patient satisfaction,” finding that for 
the most part, warfarin was well tolerated and did not pose 
heavy additional burdens or lifestyle changes; in fact, qual-
ity of life appeared to be more influenced by the patient’s 
underlying comorbid conditions.44 At the same time, the 
study acknowledged a wide range in the perceived impact 
of warfarin therapy, where ∼25% of patients stated that 
adhering to warfarin has at least some negative impact on 
their daily life. Locadia et al studied quality of life differ-
ences among younger patients (average age 60 years) treated 
with three versus 6 months of warfarin for deep venous 
thrombosis.49 Similar to studies in patients with atrial fibril-
lation, there was no difference in quality of life between the 
two groups at 6 months. Even among young (average age 
51 years), indigent, minority patients studied at two Bronx 
anticoagulation clinics, only 19% of patients on warfarin 
reported limitations in their daily life.50
While available data argue against attributing a signifi-
cant negative quality of life impact to long-term warfarin 
therapy, all of the studies have limitations. For one, we do 
not know whether quality of life would have been more 
negatively impacted in patients who were not selected to 
start warfarin; similarly, little is known about quality of 
life changes in patients who discontinued warfarin. Most 
studies were of patients who already elected to take warfa-
rin, individuals who may be at baseline more compliant or 
agreeable to chronic therapy. Greater variability in quality 
of life may be more likely in unselected patients.46,51 Also, 
for the most part, studies have evaluated older patients and 
potentially lack generalizability to younger patients who 
might experience a more pronounced quality of life detri-
ment when forced to limit activities (like sports) to prevent 
bleeding.47 Finally, the impact of experienced side effects 
(ie, bleeding), even if minor, likely plays a significant role 
in determining patient’s quality of life while taking warfarin 
and needs a more robust assessment in future quality of life 
analyses.
Several anticoagulation-specific quality of life measure-
ment tools have been developed in recent years with the 
goal of better measuring nuances related to long-term anti-
coagulation therapy effects on quality of life.43,52,53 Future 
studies using these tools, especially given the development of 
novel therapies that do not require the monitoring and dose-
adjustment burdens of warfarin,43,53 may uncover important 
details of how quality of life issues interact with patient 
experiences on long-term anticoagulation.
Adherence to anticoagulation  
in clinical trial settings
Randomized clinical trials that randomly assign patients to 
either warfarin or an alternative agent can help illuminate 
the risk of non-adherence related to warfarin, independent 
of potential confounding factors that affect the validity 
of observational studies. Because patients are randomly 
assigned to either warfarin or an alternative, risk factors that 
may be related to adherence should be equally allocated. Patient Preference and Adherence 2010:4 55
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The majority of warfarin trials have been non-blinded, where 
only patients randomized to warfarin undergo regular INR 
testing. In these studies, both medication side-effects and 
the burdens of monitoring may be factors contributing to 
non-adherence.
The original clinical trials comparing oral anticoagulants 
to placebo or aspirin did not consistently demonstrate a 
compliance difference between the two arms. Some trials 
reported higher rates of discontinuation in patients ran-
domized to oral anticoagulants16,21 while others showed no 
difference.17–19,55
The Atrial Fibrillation Clopidogrel Trial with Irbesartan 
for Prevention of Vascular Events (ACTIVE W) trial ran-
domized patients to oral anticoagulation or clopidogrel plus 
aspirin.54 The cumulative risk of permanent discontinuation 
was only 7.8% for oral anticoagulation versus 13.8% for 
clopidogrel plus aspirin. In comparison, the Birmingham 
Atrial Fibrillation Trial of the Aged (BAFTA) study found 
that elderly patients were more likely to discontinue war-
farin than aspirin therapy.20 After a mean follow-up period 
of 2.7 years, 33% of individuals randomized to warfarin 
discontinued therapy, compared to 24% of patients ran-
domized to aspirin. Notably, discontinuation rates were 
relatively high in both arms and it is possible that the 
burdens of warfarin monitoring weighed more heavily in 
elderly patients.
Newer anticoagulants, such as oral direct thrombin 
inhibitors and Factor Xa inhibitors may become promising 
alternatives to warfarin and have the advantage of fixed 
oral dosing without routine INR measurements. The Stroke 
Prevention using an Oral Thrombin Inhibitor in Atrial Fibril-
lation (SPORTIF) III trial randomized patients to open-label 
warfarin versus ximelagatran, a direct thrombin inhibitor.55 
Although ximelagatran was taken twice daily at fixed doses 
and did not require routine INR monitoring, 18% prematurely 
discontinued ximelagatran while 14% discontinued warfa-
rin. The double-blinded SPORTIF V trial, where patients 
randomized to ximelagatran had sham INR testing to mimic 
on-warfarin treatment, found no significant difference in the 
proportion of patients who chose to stop therapy (10.6% in 
the warfarin arm versus 10.0% in the ximelagatran arm).56 
The recent Randomized Evaluation of Long-Term Antico-
agulation Therapy (RE-LY) trial compared the oral direct 
thrombin inhibitor dabigatran to warfarin and showed 16.6% 
discontinued warfarin at 2 years while 21.0% discontinued 
fixed dose dabigatran.57 In a subsequent randomized trial 
comparing warfarin to dabigatran for treatment of acute DVT, 
treatment was stopped in 1.6% of patients on dabigatran for 
non-adherence compared to 2.8% of patients on warfarin, 
though the study was not designed to evaluate adherence 
rates.58
In summary, discontinuation and non-adherence rates 
on warfarin are not consistently higher than in control arms 
of randomized clinical trials, although elderly patients 
may be more likely to discontinue warfarin than aspirin. 
Extrapolating these findings to general clinical care must 
be done cautiously since randomized trials tend to recruit 
highly motivated participants who may be more compliant 
than unselected populations. Additionally, randomized tri-
als have frequent monitoring and follow-up related to the 
study, which may lead to a higher adherence rate than in 
general clinical care. Data from observational studies are 
therefore useful to examine risk factors for non-adherence 
in real-world settings.
Risk factors for poor adherence  
to warfarin therapy
Large proportions of patients in whom warfarin therapy is 
indicated do not take warfarin, particularly for atrial fibrilla-
tion.59–61 While the reasons for undertreatment are multiple, 
the failure to initiate warfarin therapy is responsible for 
a large percentage of underuse.6,9,62–64 At the same time, 
data suggest that even in patients appropriately initiated on 
warfarin therapy, many struggle to maintain adherence over 
the long term.38–40,66 Although as described above, there are 
challenges in quantifying the negative impact of warfarin 
on quality of life, several risk factors for non-adherence 
to warfarin have been identified, including younger age, 
male sex, low overall stroke risk, poor cognitive function, 
poverty, homelessness, and higher educational attainment 
(Table 2). Continuing to study and uncover contributing 
risk factors for non-adherence is important due to the cor-
relation of poor adherence to lower proportions of time spent 
in therapeutic INR ranges65–68 as well as to worse morbidity 
and mortality.69
Table 2 Factors associated with poor adherence to warfarin 
therapy
Younger age
Male sex
Low overall stroke risk
Poor cognitive function
Poverty
Homelessness
Higher educational attainment
employment
reluctant receptivity of medical informationPatient Preference and Adherence 2010:4 56
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Preliminary data from the Anticoagulation and Risk 
factors in Atrial Fibrillation (ATRIA) Study suggest that 
over one in four patients newly started on warfarin therapy 
for atrial fibrillation discontinue therapy within 1 year.70 
These results are consistent with data from clinical trials as 
discussed above showing a 22% discontinuation in the first 
year and 33% during a mean study period of 2.7 years in 
patients randomized to warfarin versus alternative agents,37,39 
as well as an observational study demonstrating that 26% 
of patients older than 79 years newly started on warfarin 
had stopped therapy within the first year.38 Although a high 
frequency of hemorrhagic events partially explained the 
significant discontinuation rate in one study,38 discontinu-
ation rates were large even in studies without many major 
bleeding episodes.37,70
Despite the higher risk of hemorrhagic complications in 
elderly patients, studies have found younger age to be a risk 
factor for poor warfarin adherence.36,71 Men and patients 
with fewer risk factors for stroke also appear to have lower 
warfarin adherence rates.36,64,71
The INR Adherence and Genetics (IN-RANGE) study 
examined the prevalence and risk factors of inconsistent 
warfarin use.72,73 Using electronic pill bottle caps to monitor 
patient adherence over 32 weeks, 92% had at least one missed 
or extra bottle opening and 36% missed more than 20% of 
the prescribed bottle openings. Analysis of the IN-RANGE 
data linked poor adherence to several risk factors, including 
education beyond high school and being actively employed, 
but also to lower mental health functioning and poor cogni-
tive functioning.74
In terms of educational attainment, the IN-RANGE 
findings are consistent with previous case-control data,71 
possibly because higher education may correspond to patient 
confidence in independent decision making or decreased 
trust in physicians. Fang et al showed that although limited 
health literacy was associated with deficits in warfarin-
related knowledge, knowledge and literacy levels were not 
significantly associated with self-reported adherence or INR 
control.75 Active employment has been found to be a risk 
factor for poor adherence for both anticoagulation as well as 
other diseases,67,76 possibly because employed patients may 
have greater competing time interests. While employment 
may be linked to poor adherence, so might extreme poverty, 
as data from an underserved urban population demonstrate an 
association with higher self-reported adherence in individuals 
with an annual income greater than $10,000.50
While race has been implicated as an independent 
risk factor for adherence of certain medications, such as 
anti-hypertensive medications,77–79 few studies have looked 
at the impact of race on adherence to warfarin regimens. 
Case-control data suggest a trend where non-compliant 
cases were more likely to be non-white.71 There is evidence 
that some warfarin related racial disparities exist, including 
worse INR testing frequency among African-American and 
Hispanic patients80 and increased likelihood of African-
Americans having subtherapeutic INRs.81 However, none of 
these studies demonstrated a difference in adherence based 
on race, and further studies are needed to understand the 
interaction, if any.
Investigation into psychosocial determinants specific to 
warfarin adherence has been limited, but evaluation of medi-
cally ill patients in general has identified multiple associated 
factors including depressive symptoms, perceived lack of 
social support, poor cognitive function, and poor health 
related quality of life.82–85 In a study of patients on warfarin 
for non-valvular atrial fibrillation, patients with presumed 
psychosocial risk factors for non-adherence, in particular 
substance abuse, had increased risk for adverse medical out-
comes, though adherence rates were not directly assessed.83 
Johnston et al found that only 9.7% of studied Medicaid 
patients with new atrial fibrillation filled a prescription for 
warfarin within 30 days of diagnosis.62 In this cohort, alcohol 
and drug abuse, psychiatric disease, homelessness, and lack 
of caregiver support were inversely related to warfarin use, 
though the study could not differentiate between patients 
who were given a prescription and failed to fill it versus those 
who never received a prescription. Cognitive functioning has 
inconsistent associations with adherence, but such studies are 
likely to be confounded by caregiver involvement.84,85
In addition to psychosocial determinants of warfarin 
use, a few studies have investigated attitudinal correlates 
to warfarin adherence. A study of patients in an academic 
anticoagulation clinic evaluated self-reported compliance 
and found that in addition to being homeless, non-married, 
and having a higher pill-burden, patients’ perceptions of 
barriers to taking warfarin correlated to worse compliance.86 
Barriers measured in this case included the perception of 
taking too many pills, the perception that taking warfarin 
increases worry about bad health outcomes, and the percep-
tion that taking warfarin increases bruising and bleeding. 
Qualitative data also hint at the potential impact of high pill 
burden as a perceived barrier warfarin adherence.44 In another 
analysis, Cruess et al found trends linking several attitudinal 
assessment scores with warfarin non-adherence.87 Of these, 
higher “Information Discomfort,” specifically a measure of 
“patient reluctance to hear information about their medical Patient Preference and Adherence 2010:4 57
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conditions and treatments,” was independently associated 
with poor adherence.
In summary, patients often struggle to maintain adher-
ence with warfarin regimens, potentially leading to more 
difficult INR control and increasing the risk for adverse 
health outcomes.72 Multiple risk factors seem to predispose 
patients to inconsistent warfarin use. Among demographic 
factors, younger age and male sex confer worse compliance, 
while elderly patients may be among the most adherent 
groups. In terms of medical comorbidities, a lower risk of 
stroke confers worse adherence as does poor cognitive func-
tioning. Indirect data suggest that multiple comorbidities 
and the associated high pill burden may enhance perceived 
barriers to warfarin adherence among patients. Hemorrhagic 
events on warfarin surely influence future drug persistence, 
but questions about the exact relationship of non-adherence 
to bleeding and the relative weight of minor versus major 
bleeding events needs further evaluation. Those with higher 
educational attainment are less likely to demonstrate warfa-
rin adherence as are those currently employed, though the 
reasons for this are not clear. Homelessness, poverty, and 
lack of social support are associated with lower adherence. 
Finally, attitudinal factors including the perception of bar-
riers to compliance and reluctant receptivity of information 
related to medical conditions may play an important role in 
determining adherence.
Ultimately, the determinants of warfarin adherence in 
an individual patient probably exist as a complex matrix of 
interacting factors. Awareness of these factors and devel-
opment of strategies to overcome their influence represent 
potentially important ways to improve not just initiation of 
warfarin therapy, but also the persistence of that therapy.
Conclusion and future  
investigations
Anticoagulant use will likely increase as the national 
and worldwide population ages in coming decades. As 
more patients are initiated on warfarin therapy and novel 
anticoagulant agents are developed, further studies are 
needed to elucidate the complex interaction of various 
factors contributing to patient adherence and persistence 
on anticoagulation. It remains unclear whether monitor-
ing burdens significantly affect subsequent persistence on 
therapy independent of the associated activity limitations and 
bleeding complications of warfarin. Measuring the relative 
impact of warfarin therapy on quality of life is challenging. 
Newer classes of oral anticoagulants including direct throm-
bin inhibitors and factor Xa inhibitors offer the promise 
of predictable pharmacokinetics and more specific factor 
targeting that will limit the need for monitoring and may 
have quality of life advantages over warfarin.88 Interestingly, 
a recent randomized trial comparing oral warfarin to the 
oral direct thrombin inhibitor dabigatran demonstrated that 
dabigatran was as good as warfarin at 6 months in prevent-
ing recurrent venous thromboemolism, and shared a similar 
safety profile, but did not require laboratory monitoring.58 
The study did not directly address quality of life differences. 
As these new drugs continue evaluation and development, 
quality of life measurement tools that are specific to anti-
coagulant therapy will be important when comparing the 
efficacy of these agents with warfarin.43
Clinicians likely influence persistence as well, as patients 
are more likely to remain on anticoagulation if they have mul-
tiple thromboembolic risk factors. Although major bleeding 
events on anticoagulation are relatively uncommon, minor 
bleeds may significantly affect both clinician and patient 
perceptions of the risk of therapy, and thus, subsequent 
persistence.
Strict adherence to anticoagulant regimens is important 
to maximize the time spent in a therapeutic anticoagulation 
intensity. In certain patient populations, such as those who 
have impaired cognition, interventions such as monthly 
medication organizers,89 interactive voice response systems,90 
compliance-linked financial incentives,91 and at-home war-
farin self-management programs,92,93 have shown promise in 
improving adherence.
Attempts to enhance adherence and persistence in 
individual patients must prioritize patient preference and 
tailor treatment options appropriately. Evidence highlights 
a dramatic interpatient variability around perceptions and 
preferences for antithrombotic prophylaxis,41 as well as 
the problematic nature of physician assumptions about 
patient preferences.45 While patient knowledge about 
warfarin therapy seems a logical target for shaping patient 
perceptions of warfarin, anticoagulation education and 
health literacy alone have not proven to independently 
predict adherence.75 Further exploration of the type and 
best delivery mode for that information will help shape 
education strategies in the future.94,95 Furthermore, it 
must be understood that in addition to overt prefer-
ences, more subtle patient attitudes – such as perceived 
adherence barriers86 and lack of receptivity to medical 
information87 – may need to be addressed for successful 
adherence. As such, future investigation should focus on 
enhancing models of patient-physician shared decision 
making around anticoagulation.46Patient Preference and Adherence 2010:4 58
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